Business Standard

Ranbaxy recalls drug in US

BS Reporter  |  New Delhi 

  • ALSO READ

    Ranbaxy finding ways to make two of four acquisitions work

    Ranbaxy pares early gains, ends flat

    Ranbaxy gains WHO pre-qualification for Indinavir - 400mg ARV capsules

    India Eco Summit: Daiichi to launch Ranbaxy's drugs in Japan

    India Eco Summit: Issues with USFDA to drag on, says Ranbaxy

India’s leading drug maker has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

This is the second instance in four months when Ranbaxy has initiated a recall. In July, the company had pulled out a lot of Sotret from the US market after it was found to be degraded. Confirming the development, a company spokesperson said the recall was carried out voluntarily and was limited to a single lot of Sotret 40 mg tablets.

According to the (USFDA), the recall comes under the Class III category, which implies that the use of or exposure to the product that is being recalled is unlikely to have any adverse health impact.

Ranbaxy recalls drug in US

India’s leading drug maker Ranbaxy has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

India’s leading drug maker has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’.

This is the second instance in four months when Ranbaxy has initiated a recall. In July, the company had pulled out a lot of Sotret from the US market after it was found to be degraded. Confirming the development, a company spokesperson said the recall was carried out voluntarily and was limited to a single lot of Sotret 40 mg tablets.

According to the (USFDA), the recall comes under the Class III category, which implies that the use of or exposure to the product that is being recalled is unlikely to have any adverse health impact.

image

Latest News